{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:41:10Z","timestamp":1793677270300,"version":"4.5.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immune checkpoint inhibitors (ICI)-induced myasthenia gravis (MG) is an uncommon but potentially fatal neurotoxicity. We aim to help physicians familiarize themselves with the clinical characteristics of ICI-induced MG, facilitating early diagnosis and prompt intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched the Chinese People\u2019s Liberation Army General Hospital medical record system from January 2017 to August 2023 for patients diagnosed with ICI-induced MG. We systematically reviewed the literature until August 2023 to identify all similar patients. We collected clinical information on these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>110 patients were identified, 9 from our institution and 101 from case reports. In our institution, Median age was 66\u2009years (range: 49\u201379\u2009years). 6 were males. The most common was lung cancer (<jats:italic>n<\/jats:italic>\u2009=\u20094). All patients had no previous history of MG and received PD-1 or PD-L1 inhibitors. The median time from ICI initiation to first MG symptoms was 4\u2009weeks (range: 2\u201315\u2009weeks). ICIs were discontinued in all patients. Most patients initially received high-dose corticosteroids, and their symptoms improved. Some patients are discharged with corticosteroids maintenance therapy. In addition, 55 patients (50%) with concomitant myositis and\/or myocarditis and MG-induced mortality were more common in the myositis and\/or myocarditis group (10.9% vs. 34.5%, <jats:italic>p<\/jats:italic>\u2009=\u20090.016). Overlap of myositis with MG (OR\u2009=\u20093.148, <jats:italic>p<\/jats:italic>\u2009=\u20090.009) and anti-AChR antibody positivity (OR\u2009=\u20093.364, <jats:italic>p<\/jats:italic>\u2009=\u20090.005) were both significantly associated with poor outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study reveals the prognosis of ICI-induced MG and suggests that myositis and\/or myocarditis are severe comorbidities of ICI-induced MG, emphasizing the importance of early diagnosis and clinical intervention.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1372861","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T13:54:20Z","timestamp":1712152460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuhui","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijuan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhefeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/annonc\/mdx755","article-title":"Comprehensive analysis of the clinical immuno-oncology landscape","volume":"29","author":"Tang","year":"2018","journal-title":"Ann Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with Cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s00415-021-10870-6","article-title":"How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update","volume":"269","author":"Vogrig","year":"2022","journal-title":"J Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with Nivolumab plus Ipilimumab or Nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and Meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/ana.20577","article-title":"A CTLA4high genotype is associated with myasthenia gravis in thymoma patients","volume":"58","author":"Chuang","year":"2005","journal-title":"Ann Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e101986","DOI":"10.1371\/journal.pone.0101986","article-title":"CTLA4 variants and haplotype contribute genetic susceptibility to myasthenia gravis in northern Chinese population","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","article-title":"Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes","volume":"95","author":"Sechi","year":"2020","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1108116","DOI":"10.3389\/fimmu.2023.1108116","article-title":"Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events","volume":"14","author":"M\u00fcller-Jensen","year":"2023","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/braincomms\/fcaa181","article-title":"Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy","volume":"2","author":"Shelly","year":"2020","journal-title":"Brain Commun"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.3747\/co.25.4047","article-title":"Predictors of immunotherapy-induced immune-related adverse events","volume":"25","author":"Kartolo","year":"2018","journal-title":"Curr Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis","volume":"86","author":"Wongvibulsin","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/onco.13740","article-title":"Temporal trends and outcomes among patients admitted for immune-related adverse events: a single-center retrospective cohort study from 2011 to 2018","volume":"26","author":"Molina","year":"2021","journal-title":"Oncologist"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12072-021-10151-4","article-title":"Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients","volume":"15","author":"Biewenga","year":"2021","journal-title":"Hepatol Int"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2021.03.012","article-title":"The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials","volume":"150","author":"Fujiwara","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/1346-8138.15408","article-title":"Rechallenge of programmed cell death 1 inhibitor after an interval with dacarbazine treatment may be effective for advanced malignant melanoma","volume":"47","author":"Kan","year":"2020","journal-title":"J Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/bjc.2014.126","article-title":"Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy","volume":"110","author":"Chiarion-Sileni","year":"2014","journal-title":"Br J Cancer"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-12-3080","article-title":"Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control","volume":"19","author":"Robert","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of Readministration of immune checkpoint inhibitors after immune-related adverse events in patients with Cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"32298","DOI":"10.18632\/oncotarget.25949","article-title":"Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer","volume":"9","author":"Niki","year":"2018","journal-title":"Oncotarget"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/jjco\/hyz066","article-title":"The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer","volume":"49","author":"Watanabe","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1007\/s00432-021-03901-2","article-title":"Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study","volume":"148","author":"Xu","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e001622","DOI":"10.1136\/jitc-2020-001622","article-title":"Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade \u22652 immune-related adverse events in patients with cancer","volume":"8","author":"Allouchery","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and Rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Oncol Pract"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/cam4.5050","article-title":"Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: a single-center case series","volume":"12","author":"Longinow","year":"2023","journal-title":"Cancer Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1372861\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T13:54:25Z","timestamp":1712152465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1372861\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":41,"alternative-id":["10.3389\/fneur.2024.1372861"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1372861","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"article-number":"1372861"}}